Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Neurological disorders are disorders that affect the central nervous system or the peripheral nervous systems and can impair the brain, spinal cord, peripheral nerve or neuromuscular function.
SARS-CoV-2 infection can be associated with ‘brain fog’ and persistent neurologic disease, especially in the elderly, with the possibility of direct viral particle interference with normal synaptic transmission.
Staging Alzheimer’s disease on the basis of the disease’s biological underpinnings might help with stratification and prognostication, both in the clinical setting and in clinical trials. We propose a staging model based on only five biomarkers, which are related to amyloid-β and tau pathologies in different ways and can be measured with a single sample of cerebrospinal fluid.
SARS-CoV-2 infection can be associated with ‘brain fog’ and persistent neurologic disease, especially in the elderly, with the possibility of direct viral particle interference with normal synaptic transmission.
Neuromodulation and brain–computer interfaces are rapidly evolving fields with distinct origins but with the shared goal of improving the lives of people with neurological and psychiatric disorders or injuries. Their increasing technological overlap provides new opportunities for collaborative work and rapid progress in neurotechnology.
Findings of phase III trials of the Bruton’s tyrosine kinase inhibitor evobrutinib in patients with relapsing multiple sclerosis were recently presented at the ACTRIMS Forum.
New data recently reported at the ACTRIMS Forum add to growing evidence of an aetiological role for Epstein–Barr virus infection in multiple sclerosis.
